Anti-TNF-α antibody has been applied in phase I and II clinical cancer trials, and evaluated as partial disease stabilization effects.251–253 The current anti-TNF-α antibodies approved by FDA include infliximab, adalimumab and golimumab.254 Infliximab is proved to be well tolerated without dose-limiting toxic effects in advanced cancer by clinical studies,255 and seven in forty-one patients treated with infliximab show disease stabilization.255. The gene discussed is TNF; the disease is cancer.